Q4 2025 · 13F-HR
Elmind Capital, LPholdings as filed
Filed 2026-02-17 · accession 0001013594-26-000245
$338.9M
Reported value
34
Positions
2025-12-31
Period end
The Brief · Elmind Capital, LP · Q4 2025
AI · grounded in 13F
Elmind Capital, LP established a new position in COGT valued at $41.6M. The fund also initiated new stakes in SNDX for $39.0M and VRDN for $26.7M. Additional new positions include VERA at $24.4M and CLDX at $23.5M. The fund ended the period with 34 positions and total AUM of $338.9M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $41.6M | 12.3% | 1,170,740 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $39.0M | 11.5% | 1,855,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $26.7M | 7.89% | 858,631 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $24.4M | 7.21% | 482,500 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $23.5M | 6.93% | 865,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $20.4M | 6.03% | 492,500 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $16.8M | 4.95% | 2,150,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $13.4M | 3.97% | 291,500 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $13.2M | 3.90% | 476,338 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $13.2M | 3.90% | 475,750 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $12.9M | 3.82% | 801,300 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $10.5M | 3.09% | 679,900 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $9.2M | 2.72% | 350,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $8.7M | 2.58% | 460,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $7.6M | 2.25% | 447,846 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $6.7M | 1.96% | 211,000 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $5.4M | 1.60% | 22,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $5.4M | 1.58% | 11,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $4.9M | 1.44% | 82,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $4.5M | 1.34% | 536,946 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $4.2M | 1.24% | 110,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $3.3M | 0.98% | 38,000 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $3.2M | 0.95% | 310,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $3.1M | 0.92% | 90,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $3.0M | 0.88% | 700,000 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $2.3M | 0.69% | 100,000 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $2.0M | 0.60% | 58,248 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $2.0M | 0.58% | 207,900 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $1.9M | 0.56% | 210,000 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $1.4M | 0.41% | 900,000 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $1.4M | 0.40% | 112,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $1.3M | 0.37% | 50,000 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $994,000 | 0.29% | 20,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $744,450 | 0.22% | 30,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.